Barinthus Biotherapeutics (BRNS) Income from Continuing Operations (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Income from Continuing Operations of 5534000.0 for Q1 2026, up 71.85% on a YoY basis from 3220276.24 in Q1 2025, and up 50.16% quarter-over-quarter from 11103000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 5534000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 71.85% year-over-year to 5534000.0; the trailing twelve-month figure through Mar 2026 stood at 52334000.0 (up 19.88% YoY), and the FY2025 full-year result was 66458000.0, down 8.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 5534000.0, up from 11103000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 15689000.0 in Q2 2022, with the low at 23824000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 11841235.29 across 5 years, with a median of 15520000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 248.69% — and 2023, when it sank 807.96%.
- Barinthus Biotherapeutics' Income from Continuing Operations stood at 21163000.0 in 2022, then grew by 18.3% to 17290000.0 in 2023, then decreased by 19.09% to 20591000.0 in 2024, then jumped by 46.08% to 11103000.0 in 2025, then surged by 50.16% to 5534000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5534000.0 (Q1 2026), 11103000.0 (Q4 2025), and 14571000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | -5.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.53 Mn |
| Dec 31, 2025 | -11.10 Mn |
| Sep 30, 2025 | -14.57 Mn |
| Jun 30, 2025 | -21.13 Mn |
| Mar 31, 2025 | -19.66 Mn |
| Dec 31, 2024 | -20.59 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -16.94 Mn |
| Mar 31, 2024 | -15.52 Mn |
| Dec 31, 2023 | -17.29 Mn |
| Sep 30, 2023 | -14.11 Mn |
| Jun 30, 2023 | -23.82 Mn |
| Mar 31, 2023 | -18.22 Mn |
| Dec 31, 2022 | -21.16 Mn |
| Sep 30, 2022 | 8.22 Mn |
| Jun 30, 2022 | 15.69 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | -16.72 Mn |
| Sep 30, 2021 | -5.53 Mn |
| Jun 30, 2021 | -16.86 Mn |